These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24837642)

  • 1. A case of rasagiline-induced spontaneous orgasms in a female patient.
    Uca AU; Kozak HH
    Parkinsonism Relat Disord; 2014 Aug; 20(8):929-30. PubMed ID: 24837642
    [No Abstract]   [Full Text] [Related]  

  • 2. Rasagiline induced hypersexuality in Parkinson's disease.
    Reyes D; Kurako K; Galvez-Jimenez N
    J Clin Neurosci; 2014 Mar; 21(3):507-8. PubMed ID: 24055209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasagiline-induced spontaneous ejaculation.
    Chuang RS; Lang AE
    Mov Disord; 2009 Oct; 24(14):2160-1. PubMed ID: 19735087
    [No Abstract]   [Full Text] [Related]  

  • 4. Spontaneous unwelcome orgasms due to pramipexole and ropinirole.
    Kaut O; Asmus F; Paus S
    Mov Disord; 2012 Sep; 27(10):1327-8. PubMed ID: 22903628
    [No Abstract]   [Full Text] [Related]  

  • 5. Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Valentino F; Cosentino G; Fierro B; Realmuto S; Mastrilli S; Savettieri G; D'Amelio M
    Neurol Sci; 2015 Dec; 36(12):2305. PubMed ID: 26335016
    [No Abstract]   [Full Text] [Related]  

  • 6. Rasagiline and Pisa syndrome in Parkinson's disease patients.
    Solla P; Cannas A; Orofino G; Marrosu F
    Neurol Sci; 2015 Mar; 36(3):485-6. PubMed ID: 25481627
    [No Abstract]   [Full Text] [Related]  

  • 7. Rasagiline in Parkinson's disease: the show must go on.
    Jost WH
    Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 9. Insidious onset of Pisa syndrome after rasagiline therapy in a patient with Parkinson's disease.
    Valentino F; Cosentino G; Fierro B; Realmuto S; Mastrilli S; Savettieri G; D'Amelio M
    Neurol Sci; 2014 Oct; 35(10):1615-7. PubMed ID: 24770981
    [No Abstract]   [Full Text] [Related]  

  • 10. Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinson's disease.
    Odiyoor M; Kobylecki C; Hackett RJ; Silverdale MA; Kellett MW
    Mov Disord; 2009 Dec; 24(16):2434-5. PubMed ID: 19891000
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease.
    Kanovský P; Bares M; Pohanka M; Rektor I
    J Neurol; 2002 Jan; 249(1):112-4. PubMed ID: 11954860
    [No Abstract]   [Full Text] [Related]  

  • 13. Impulse control disorders induced by rasagiline as adjunctive therapy for Parkinson's disease: report of 2 cases.
    Vitale C; Santangelo G; Erro R; Errico D; Manganelli F; Improta I; Moccia M; Barone P
    Parkinsonism Relat Disord; 2013 Apr; 19(4):483-4. PubMed ID: 23305965
    [No Abstract]   [Full Text] [Related]  

  • 14. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
    Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM;
    Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients.
    Weintraub D; Koester J; Potenza MN; Siderowf AD; Stacy M; Voon V; Whetteckey J; Wunderlich GR; Lang AE
    Arch Neurol; 2010 May; 67(5):589-95. PubMed ID: 20457959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical manifestation of confusion and hallucinations caused by an interaction between rasagiline and escitalopram].
    Bandrés Liso AC; Toyas Miazza C
    Farm Hosp; 2009; 33(3):173-5. PubMed ID: 19712602
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
    Parkinson Study Group
    Arch Neurol; 2004 Apr; 61(4):561-6. PubMed ID: 15096406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.